David Bergstrom

David Bergstrom has over 30 years of experience in the pharmaceutical and healthcare industries. David began their career in 1990 as Director of Pharmaceutical and Analytical Development at Hoechst Marion Roussel (sanofi aventis predecessor company). In 1998, they moved to Guilford Pharmaceuticals as Vice President of Chemical and Pharmaceutical Development. In 1999, they joined Cardinal Health, Inc. as Senior Vice President and General Manager, where they were responsible for building the business from a zero basis to $40MM annual revenue. In 2006, they became Senior Vice President and Chief Operating Officer of NovaDel Pharma Inc., where they were the principal technical lead on partnering and in/out-licensing discussions. In 2012, they moved to Advantar Laboratories, Inc. as Executive Vice President and Chief Operating Officer. In 2013, they joined Antares Pharma Inc. as Senior Vice President of Pharmaceutical Development for Drug Device Combination Products. In 2015, they moved to DHB INSIGHTS LLC as Pharmaceutical Development Senior Vice President for Drug/Device Products/Analytical/Manufacturing/Quality/Clinical. In 2017, they became a Senior Consultant at Kenexum. Most recently, in 2018, they joined Bridge Therapeutics Inc. as Chief Executive Officer, where they are leading the company's day-to-day new product development efforts in advancing its pipeline in the opioid addiction and chronic pain therapeutic spaces. In 2022, they became CEO and Chairman of Board of MyCo Healthcare Solutions.

David Bergstrom obtained a Bachelor of Pharmacy (B.Pharm.) from Ferris State University, a Master of Science (M.S.) in Pharmaceutical Chemistry from The University of Michigan, and a Doctor of Philosophy (PhD) in Pharmaceutics from the University of Utah.